Subpotent Blood Pressure Drug Recalled

Boehringer Ingelheim Pharmaceuticals Inc is recalling 15,198 bottles of Micardis tablets because the drug is subpotent, according to the June 9, 2021, US Food and Drug Administration (FDA) Enforcement Report. 

The recall is for 80-mg Micardis (telmisartan) tablets, 30-count cartons (NDC 0597-0041-37), from lot 860412 (Exp. 9/22). Boehringer Ingelheim Pharmaceuticals distributed the tablets in Arkansas, Colorado, Connecticut, Louisiana, North Carolina, North Dakota, New Hampshire, New Jersey, Ohio, Pennsylvania, and Puerto Rico. 

Boehringer Ingelheim Pharmaceuticals voluntarily initiated the recall May 4, 2021. On May 28, 2021, the FDA designated it Class II, signaling use of the tablets could cause temporary or medically reversible adverse health consequences. A remote possibility of serious harm also exists.

Micardis is a prescription angiotensin II receptor blocker used to treat hypertension.